Lewis Asset Management LLC Has $271,000 Holdings in Pfizer Inc. (NYSE:PFE)

Lewis Asset Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 68.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,226 shares of the biopharmaceutical company's stock after selling 22,613 shares during the period. Lewis Asset Management LLC's holdings in Pfizer were worth $271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank increased its position in Pfizer by 0.6% in the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after acquiring an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the period. Empowered Funds LLC lifted its holdings in shares of Pfizer by 80.9% during the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock worth $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC grew its position in Pfizer by 394.2% in the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock valued at $1,512,000 after buying an additional 41,668 shares during the last quarter. Finally, KBC Group NV increased its stake in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after buying an additional 639,985 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded up $0.27 during mid-day trading on Thursday, hitting $26.89. 32,270,209 shares of the company's stock traded hands, compared to its average volume of 35,838,855. The firm has a 50 day moving average price of $26.22 and a 200 day moving average price of $27.90. The company has a market cap of $152.41 billion, a PE ratio of 36.34, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. Pfizer's payout ratio is presently 227.03%.

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target on the stock. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a "market perform" rating and a $32.00 price objective for the company. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.